Protein disulfide isomerase inhibition synergistically enhances the efficacy of sorafenib for hepatocellular carcinoma.
Jae-Kyung WonSu Jong YuChae Young HwangSung-Hwan ChoSang-Min ParkKwangsoo KimWon-Mook ChoiHyeki ChoEun Ju ChoJeong-Hoon LeeKyung Bun LeeYoon Jun KimKyung-Suk SuhJa-June JangChung Yong KimJung-Hwan YoonKwang-Hyun ChoPublished in: Hepatology (Baltimore, Md.) (2017)
These results suggest that PDI is a promising therapeutic target for enhancing the efficacy of sorafenib and can also be a biomarker for predicting sorafenib responsiveness. (Hepatology 2017;66:855-868).
Keyphrases